Junshi Bio FY revenue 2.50B yuan

Shanghai Junshi Biosciences (HKEX: 1877) reported total revenue of RMB1,503 million for the fiscal year ending December 2023, reflecting a 58% year-over-year increase in pharmaceutical product sales. Revenue from its flagship product, TUOYI® (toripalimab), reached RMB919 million, a 25% rise compared to 2022. The company attributed this growth to expanded commercialization efforts and new indication approvals, including conditional marketing authorization for MINDEWEI, an anti-SARS-CoV-2 drug, and multiple supplemental new drug applications for TUOYI® in oncology.

Despite revenue growth, Junshi Biosciences incurred a net loss of RMB2,282 million in 2023, down from RMB2,386 million in 2022. Research and development (R&D) expenses totaled RMB1,937 million, a 19% decline driven by strategic reallocation of resources toward high-potential pipelines, including antibody-drug conjugates, bispecific antibodies, and nucleic acid therapies. The company's valuation metrics indicate a price-to-sales (PS) ratio of 7.2x, above the peer average of 5.6x but below the U.S. biotech industry average of 12.2x. Analysts note that while the stock trades significantly below estimated future cash flow value ($11.78 vs. current $3), insufficient data limits confidence in price forecasts.

Junshi Biosciences continues to expand its global footprint, securing FDA and TGA approvals for toripalimab in nasopharyngeal carcinoma and entering licensing agreements for market access in over 20 countries. With 30+ candidates in clinical trials and partnerships to diversify its therapeutic pipeline, the company remains focused on addressing unmet needs in oncology and infectious diseases.